SEC Comment Letter 0000000000-24-012864 to GYRE THERAPEUTICS, INC. (GYRE) (CIK 0001124105) (GYRE)
GYRE THERAPEUTICS, INC. (GYRE) (CIK 0001124105)
Date: Nov. 20, 2024 · CIK: 0001124105 · Accession: 0000000000-24-012864
AI Filing Summary & Sentiment
File numbers found in text: 333-283237
Letter
November 20, 2024 Han Ying Chief Executive Officer Gyre Therapeutics, Inc 12770 High Bluff Drive Suite 150 San Diego, CA 92130 Re:Gyre Therapeutics, Inc Registration Statement on Form S-3 Filed November 14, 2024 File No. 333-283237 Dear Han Ying: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Candice D. Johnson
Show Raw Text
November 20, 2024
Han Ying
Chief Executive Officer
Gyre Therapeutics, Inc
12770 High Bluff Drive
Suite 150
San Diego, CA 92130
Re:Gyre Therapeutics, Inc
Registration Statement on Form S-3
Filed November 14, 2024
File No. 333-283237
Dear Han Ying:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Candice D. Johnson